A design thesis for the device that closes the loop.
Pre-prototype · Concept IP · This is the thesis.
The wearable is a single insulated housing worn against the skin. The band senses. The reservoir holds the dose at temperature. The cartridge swaps. The port delivers. Every part exists in shipping medical hardware today — no one has shipped them as one closed loop.
Remote Patient Monitoring is a $16 billion industry. It measures heart rate, SpO2, respiratory rate, skin temperature. It transmits that data to a dashboard. And when a patient is dying, the intervention is a phone call.
Monitoring without intervention is observation, not care.
Healthcare technology follows a consistent pattern: observe, then intervene. Diagnostic imaging preceded surgical robotics. CGM preceded automated insulin delivery. Remote telemetry preceded the implantable defibrillator. The monitoring technology matures first. Then intervention follows.
RPM is the observation layer. It is mature, reimbursed, and growing at 12.6% annually. The intervention layer has no commercial product.
Remote Medication Delivery is the term for that layer. The term is original to SmartShot. RMD describes any system that combines continuous biosensing, algorithmic detection, and autonomous medication delivery in a wearable form factor.
Where RPM observes, RMD intervenes. SmartShot is a design thesis for the device that closes the loop.
Each target pairs a life-threatening emergency with a proven drug, a detectable biosignal, and a clear regulatory analogue.
SmartShot is not a fully autonomous device. A 24/7 staffed medical command center provides human oversight for every injection decision. Licensed paramedics and nurses monitor incoming alerts and make the final call when device confidence falls below the autonomous threshold.
This creates a four-tier response model. The tiers are the product.
This makes SmartShot a telemedicine-supervised system, not an autonomous injector. That distinction is the FDA pathway.
Devon uses fentanyl alone at 11:40 PM. At 11:41, his respiratory rate drops below 6. SpO2 hits 83%. The device registers both signals. Confidence: 99.94%. Tier 1 fires. Naloxone delivers subcutaneously at 11:41:03. Hub is notified. EMS dispatched automatically. Devon's SpO2 begins recovering at 11:42. He wakes disoriented at 11:44. Hub operator confirms vitals trending normal at 11:45. Total elapsed time from detection to delivery: three seconds. The naloxone was in the kitchen drawer for two years. It was on his arm for nine days.
No commercial product exists that integrates emergency detection with autonomous medication delivery. Detection is FDA-cleared. Delivery is proven at scale. No one has connected them in a product that shipped.
The closest precedent: Closed-loop insulin delivery. Medtronic 780G, Omnipod 5, Tandem Control-IQ. Millions of patients. FDA-cleared. Sense-decide-deliver in a wearable, running autonomously, at scale. The architecture is proven for maintenance dosing. No one has carried it into emergency medication.
Who could enter: Medtronic has the closest device engineering capabilities. Abbott has the biosensor infrastructure. Masimo has the detection layer already cleared. None have announced RMD programs. The window exists because the category hasn't been named.
Once the sense-decide-deliver architecture validates on opioid overdose, the same hardware accepts new drug cartridges and new detection algorithms. The platform extends without new device engineering.
None of these ship before the beachhead validates. They exist here because the architecture is modular by design, not because we're building seven products at once.
Three markets converge here: wearable drug delivery, crisis intervention, and closed-loop medical devices. Each is large. The intersection has no commercial entrant.
Razor-and-blade. The device is the razor — one hardware sale. The cartridge is the blade. The hub is the recurring margin underneath it all.
This is pre-seed, pre-prototype intellectual property. The value is in the design thesis, the category naming, the beachhead analysis, and the regulatory pathway research.
SmartShot is not a product. It is a design thesis backed by a registered entity, a complete documentation canon, and a clear-eyed assessment of what would need to be true. The work done so far is the work that makes the next conversation possible.
Claims sourced. Numbers cited. The whole argument in six documents.
Joe Nalley is Staff Vice President of Carelon Growth (Elevance Health's specialty health-services arm), where he owns six high-acuity clinical risk books — MSK, Oncology, CHF, Maternity, Autoimmune, and Dementia — across $50B+ in specialty medical spend. He built and sold a 13-location integrated health system (200,000+ patients served) and founded and sold ClearBill, a billing-integrity platform that returned $9.2M to payers in its first six months of full deployment. SmartShot is concept IP, not yet a company — the operating record is why the thesis is worth reading.